Drawing on the company’s Latin name, Viatris – the proposed combination of Mylan and Upjohn – has unveiled a logo and branding “capturing the company’s commitment to access, leadership and partnership.”
With the deal now ever closer following recent approval from Mylan’s shareholders, Mylan and Pfizer’s Upjohn off-patent and mature brands unit have unveiled the logo and branding for Viatris, the proposed combination of the two firms through a merger which is set to complete by the end of this year.
According to the companies, the new logo and branding is designed to “reflect Viatris’ guiding principles that will redefine the...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
